New submental and under-eye applicators expand its non-invasive facial rejuvenation capabilities.
Emface, a non-invasive facial treatment designed to treat both the skin and underlying muscles for a more youthful, lifted appearance, has reached 1 million treatments worldwide in under two years.
“The ability to stimulate elevator muscles allows us to lift facial features from within—something that was never possible before with injectables or traditional energy-based devices,” says Yael Halaas, MD, FACS, a facial plastic surgeon from NYC, USA.
Developed by BTL, Emface has expanded its capabilities over the past year with the introduction of specialized submental and under-eye applicators. The latest eye applicators received positive feedback from attending medical experts upon their launch at the IMCAS World Conference in Paris in January 2025, according to a release from the company.
“Emface isn’t just a procedure—it’s a facial multiplatform that allows us to treat different areas based on each patient’s unique needs. It’s a game-changer for anyone looking for natural-looking facial rejuvenation,” says Kyungkook Hong, MD, PhD, a board-certified dermatologist from Seoul, Korea.
More practitioners continue to integrate Emface into their treatment offerings, according to the company.
“Reaching 1 million treatments in just two years is a testament to Emface’s groundbreaking technology and the value it brings to medical professionals,” says Tomas Schwarz, CEO of BTL, in a release. “We remain committed to expanding this platform and further advancing non-invasive facial treatments in the years ahead.”
BTL’s products include Emsculpt Neo, Emface, Exion, Emsella, Exomind, as well as HIFEM, HIFES, and EXOTMS procedures.
Photo caption: Before and after photos of a patient receiving Emface
Photo credit: BTL courtesy of Joel L. Cohen, MD
